/JANX
JANX Stock - Janux Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$13.79-1.78%
$0.25 (-1.78%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.9
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.7
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+206.4%upside
Target: $42.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for JANX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$13.65 – $13.93
TARGET (TP)$42.25
STOP LOSS$12.69
RISK/REWARD1:25.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.81
52W High$61.59
52W Low$13.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.59M | $8.08M | $8.61M | $3.64M | N/A |
| Gross Profit | $8.53M | $6.13M | $7.77M | $3.64M | $-13,000 |
| Gross Margin | 80.5% | 75.8% | 90.2% | 100.0% | N/A |
| Operating Income | $-98,847,000 | $-72,979,000 | $-67,091,000 | $-32,929,000 | $-4,843,000 |
| Net Income | $-68,994,000 | $-58,293,000 | $-63,059,000 | $-32,672,000 | $-6,784,000 |
| Net Margin | -651.6% | -721.2% | -732.2% | -898.3% | N/A |
| EPS | $-1.28 | $-1.32 | $-1.52 | $-0.79 | $-0.16 |
Company Overview
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
12
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
12 Bullish0 Neutral/Bearish
Price Targets
$66
Average Target
↑ 379.6% Upside
Now
$24
Low
$66
Average
$100
High
Based on 15 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 18th 2025 | Wolfe Research | Initiation | Peer Perform | - |
| September 17th 2025 | Barclays | Initiation | Overweight | $47 |
| September 10th 2025 | Stifel | Initiation | Buy | $45 |
| September 10th 2025 | Truist | Initiation | Buy | $100 |
| September 4th 2025 | Guggenheim | Initiation | Buy | $72 |
| August 19th 2025 | Piper Sandler | Initiation | Overweight | $42 |
| July 11th 2025 | Raymond James | Initiation | Outperform | $65 |
| December 3rd 2024 | BTIG Research | Reiterated | Buy | $100← $82 |
| December 3rd 2024 | H.C. Wainwright | Reiterated | Buy | $70← $63 |
| November 22nd 2024 | Leerink Partners | Initiation | Outperform | $79 |
| October 24th 2024 | UBS | Initiation | Buy | $69 |
| September 6th 2024 | Stifel | Initiation | Buy | $70 |
| May 30th 2024 | Scotiabank | Initiation | Sector Perform | $47 |
| March 21st 2024 | BTIG Research | Initiation | Buy | $62 |
| March 20th 2024 | Cantor Fitzgerald | Initiation | Overweight | $100 |
Earnings History & Surprises
JANXBeat Rate
67%
Last 18 quarters
Avg Surprise
-10.6%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.39
Q4 2025
EPS Surprise History
Q1 24
+32.4%
$-0.25vs$-0.37
Q2 24
+14.3%
$-0.30vs$-0.35
Q3 24
+65.6%
$-0.11vs$-0.32
Q4 24
-37.8%
$-0.51vs$-0.37
Q1 25
+26.5%
$-0.36vs$-0.49
Q2 25
+11.6%
$-0.38vs$-0.43
Q3 25
-14.6%
$-0.55vs$-0.48
Q4 25
+35.0%
$-0.39vs$-0.60
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.65 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.60 | $-0.39 | +35.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.48 | $-0.55 | -14.6% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.43 | $-0.38 | +11.6% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.49 | $-0.36 | +26.5% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.37 | $-0.51 | -37.8% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.32 | $-0.11 | +65.6% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.35 | $-0.30 | +14.3% | ✓ BEAT |
Q1 2024 | Mar 8, 2024 | $-0.37 | $-0.25 | +32.4% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.46 | $-0.25 | +45.7% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.52 | $-0.42 | +19.2% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.49 | $-0.42 | +14.3% | ✓ BEAT |
Q1 2023 | Mar 10, 2023 | $-0.45 | $-0.39 | +13.3% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.51 | $-0.40 | +21.6% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.37 | $-0.41 | -10.8% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.37 | $-0.32 | +13.5% | ✓ BEAT |
Q1 2022 | Mar 18, 2022 | $-0.30 | $-0.33 | -10.0% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.17 | $-0.26 | -52.9% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.13 | $-0.62 | -376.9% | ✗ MISS |
Latest News
Barclays Maintains Overweight on Janux Therapeutics, Lowers Price Target to $29
➖ NeutralBenzinga•Dec 17, 2025, 05:47 PM•Also:
Stifel Maintains Buy on Janux Therapeutics, Lowers Price Target to $38
📈 PositiveBenzinga•Dec 2, 2025, 05:09 PM•Also:
Clear Street Maintains Buy on Janux Therapeutics, Lowers Price Target to $32
📈 PositiveBenzinga•Dec 2, 2025, 02:08 PM
B of A Securities Maintains Buy on Janux Therapeutics, Lowers Price Target to $49
➖ NeutralBenzinga•Dec 2, 2025, 01:48 PM
Janux Therapeutics shares are trading lower. The company announced updated interim data for its JANX007.
📉 NegativeBenzinga•Dec 2, 2025, 12:51 PM
Cantor Fitzgerald Maintains Overweight on Janux Therapeutics, Lowers Price Target to $150
➖ NeutralBenzinga•Dec 2, 2025, 12:33 PM
HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Lowers Price Target to $45
➖ NeutralBenzinga•Dec 2, 2025, 12:05 PM
Janux reports positive phase 1 results for JANX007 in mCRPC; stock down
➖ NeutralSeeking Alpha•Dec 2, 2025, 09:07 AM
Janux Therapeutics shares are trading lower. The company announced updated interim data for its JANX007.
📉 NegativeBenzinga•Dec 1, 2025, 09:25 PM
Janux Therapeutics Data From Phase 1 Clinical Study Of JANX007 Demonstrates High Prostate-Specific Antigen Response Rates, Deep PSA Declines
📈 PositiveBenzinga•Dec 1, 2025, 09:09 PM
HC Wainwright & Co. Reiterates Buy on Janux Therapeutics, Maintains $70 Price Target
📈 PositiveBenzinga•Nov 25, 2025, 12:12 PM
Janux Therapeutics CEO To Provide Update On JANX007 Primarily Focused On Phase 1a Dose Escalation Data And Secondarily On Phase 1b Expansion Data In Adult Subjects With mCRPC
➖ NeutralBenzinga•Nov 24, 2025, 01:06 PM
Wolfe Research Initiates Coverage On Janux Therapeutics with Peer Perform Rating
➖ NeutralBenzinga•Nov 18, 2025, 05:20 PM
Barclays Maintains Overweight on Janux Therapeutics, Raises Price Target to $48
📈 PositiveBenzinga•Nov 7, 2025, 03:31 PM•Also:
Janux Therapeutics Q3 EPS $(0.39) Beats $(0.60) Estimate, Sales $10.000M Beat $2.929M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 10:15 PM
Janux Therapeutics gains amid renewed takevover speculation
📈 PositiveSeeking Alpha•Oct 28, 2025, 02:11 PM
Watching Janux Therapeutics; Shares Move Higher, Traders Circulate Unconfirmed Rumor That Co Is Seeing M&A Interest
📈 PositiveBenzinga•Oct 28, 2025, 01:57 PM
Barclays Initiates Coverage On Janux Therapeutics with Overweight Rating, Announces Price Target of $47
📈 PositiveBenzinga•Sep 17, 2025, 10:51 AM•Also:
Truist Securities Initiates Coverage On Janux Therapeutics with Buy Rating, Announces Price Target of $100
📈 PositiveBenzinga•Sep 10, 2025, 01:19 PM
Stifel Reinstates Buy on Janux Therapeutics, Announces $45 Price Target
📈 PositiveBenzinga•Sep 10, 2025, 12:32 PM•Also:
Frequently Asked Questions about JANX
What is JANX's current stock price?
Janux Therapeutics, Inc. (JANX) is currently trading at $13.79 per share. The stock has moved -1.78% today.
What is the analyst price target for JANX?
The average analyst price target for JANX is $42.25, based on 1 analyst.
What sector is Janux Therapeutics, Inc. in?
Janux Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is JANX's market cap?
Janux Therapeutics, Inc. has a market capitalization of $0.83 billion, making it a small-cap company.
Does JANX pay dividends?
No, Janux Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
HRMY
Harmony Biosciences Holdings, Inc.
$37.81
Mkt Cap: $2.2B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
MAZE
Maze Therapeutics, Inc.
$41.71
Mkt Cap: $2.0B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
SION
Sionna Therapeutics, Inc.
$42.37
Mkt Cap: $1.9B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to JANX for comparison